Maravai LifeSciences (NASDAQ:MRVI) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Maravai LifeSciences has received a Sell (D-) rating from Weiss Ratings, indicating a negative outlook from analysts.
• The Royal Bank of Canada has decreased its price target for the stock from $7.00 to $5.00 while maintaining an "outperform" rating.
• Maravai LifeSciences' current stock price is $3.30, with a market cap of $841.41 million and an average rating of "Hold" from analysts.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

Separately, Royal Bank Of Canada reduced their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Maravai LifeSciences currently has an average rating of "Hold" and an average target price of $5.22.

Maravai LifeSciences Stock Down 0.2%

MRVI traded down $0.01 during trading on Tuesday, reaching $3.30. 428,038 shares of the stock traded hands, compared to its average volume of 2,215,391. The stock has a market cap of $841.41 million, a price-to-earnings ratio of -2.42 and a beta of 0.33. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $8.53. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The stock's 50-day simple moving average is $2.66 and its two-hundred day simple moving average is $2.38.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently made changes to their positions in the business. Philosophy Capital Management LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at approximately $5,731,000. Tejara Capital Ltd raised its holdings in Maravai LifeSciences by 257.8% in the 2nd quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company's stock valued at $4,679,000 after acquiring an additional 1,398,900 shares in the last quarter. 12 West Capital Management LP raised its holdings in Maravai LifeSciences by 8.0% in the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock valued at $27,672,000 after acquiring an additional 930,000 shares in the last quarter. Deutsche Bank AG raised its holdings in Maravai LifeSciences by 67.6% in the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company's stock valued at $4,580,000 after acquiring an additional 835,600 shares in the last quarter. Finally, First Pacific Advisors LP acquired a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $1,787,000. Institutional investors and hedge funds own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.